D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: a Prospective, Single-arm, Phase II Clinical Study

Launched by FUJIAN PROVINCIAL HOSPITAL · Oct 13, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with unresectable intrahepatic cholangiocarcinoma, a type of cancer that occurs in the liver and cannot be surgically removed. The study is looking at a combination of three treatments: D-TACE-HAIC (a specialized therapy that delivers chemotherapy directly to the liver), Envafolimab (a type of immunotherapy that helps the immune system fight cancer), and Lenvatinib (a medication that slows cancer growth). This trial is currently recruiting participants who are between 18 and 75 years old, have specific liver function scores, and have not received prior treatments for their cancer.

Participants in this trial can expect to undergo regular assessments to monitor their health and response to the treatment. It’s important for potential participants to know that they should not have had any prior anti-cancer treatments, certain medical conditions, or any serious infections before joining the study. Women of childbearing age will need to agree to use contraception during the trial and for six months afterward. This trial aims to provide valuable information about the safety and effectiveness of this new treatment combination for patients facing this challenging cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ages of 18 and 75;
• • 2. Child-Pugh liver function grade: A/B;
• • 3. ECOG score (see annex for scoring standards) : ≤1 score;
• • 4. ICC was confirmed by pathology and evaluated by two senior hepatobiliary surgeons as unresectable for surgery (including multiple intrahepatic lesions, local vascular invasion, local lymph node metastasis, and distant metastasis);
• • 5. According to RECIST 1.1 criteria, the patient has at least one measurable lesion (the CT/MRI scan diameter of the lesion can be measured ≥10mm, and the lesion has not received local treatment such as radiotherapy or freezing);
• • 6. The expected survival time is greater than 3 months;
• • 7. Patients who had not received any tumor-related targeting, immunization, radiotherapy or chemotherapy before enrollment;
• • 8. Functional indexes of vital organs met the following requirements: · Routine blood: absolute neutrophil count ≥1.5×109/L, Hb≥9.0g/L, PLT≥75×109/L; · Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN) (≤2.5 times ULN after biliary drainage in patients with obstructive jaundice); Alanine aminotransferase (ALT), aspartate aminotransferase (AST)≤ 5x ULN, albumin ≥30g /L; · Renal function: serum creatinine ≤1.5mg/dL, creatinine clearance ≥60ml /min; · Coagulation function: International standardized ratio (INR) and activated partial thromboplastin time (APTT)≤1.5 times ULN;
• • 9. No history of severe arrhythmia or heart failure; No history of severe ventilation dysfunction or severe pulmonary infection;
• • 10. Women of childbearing age should agree to use contraception during the use of medication and for 6 months after the end of medication; Patients who had a negative serum or urine pregnancy test in the 7 days prior to study enrollment and must be non-lactating patients, men should consent to use contraception during the study period and for 6 months after the end of the study period.
• Exclusion Criteria:
• • 1. Patients who have previously received other local anti-tumor treatments (such as radiotherapy, radiofrequency ablation, etc.), who are allowed to relapse 6 months after previous surgery, and who are allowed to undergo biliary drainage (including PTCD and biliary stent implantation);
• • 2. History of allergy to gemcitabine, oxaliplatin, Envolizumab, Renvastinib and its components;
• • 3. A history of other malignant tumors within the past 5 years or at the same time, except cured basal cell carcinoma of the skin, cervical carcinoma in situ and thyroid papillary carcinoma;
• • 4. Patients who have previously received an organ transplant or are planning to receive an organ transplant;
• • 5. The presence of any active autoimmune disease or patients with autoimmune disease and expected recurrence (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes);
• • 6. History of immune deficiency; The patient is taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes and continues to use it within 2 weeks prior to signing the informed consent;
• • 7. Known hereditary or acquired bleeding (e.g. coagulation disorders) or thrombotic tendencies, e.g. in hemophiliacs; Is currently or recently (within 10 days prior to the start of study therapy) used full dose oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (prophylactic use of low-dose aspirin, low-molecular weight heparin permitted);
• • 8. Serious infections, such as severe pneumonia, bacteremia, and comorbiditis requiring hospitalization, occurred within 4 weeks prior to the first use of the study drug; Baseline chest imaging findings indicate active lung inflammation, signs and symptoms of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment (excluding prophylactic antibiotic use);
• • 9. Patients with mental illness; Have a history of psychotropic substance abuse, alcoholism and drug use;
• • 10. Pregnant or lactating women;
• • 11. Those who, according to the judgment of the researcher, should not participate in this experiment for other reasons;